Press Room

Latest
News

Stay updated with the latest developments, research breakthroughs, and company announcements.

Featured
WALL STREET JOURNAL
PRESS COVERAGE December 2022

How AI That Powers Chatbots and Search Queries Could Discover New Drugs

Dr. Lurong Pan, founder of Ainnocence, discusses how natural language processing—the same AI technology behind ChatGPT—can revolutionize drug discovery by analyzing and synthesizing proteins. The approach exploits the fact that biological codes, like search queries and email texts, are represented by a series of letters.

LP

Dr. Lurong Pan

Founder & CEO

Read Article

How sequence-based AI achieves whole genome screening for billions of candidates in hours

The platform has been applied across 60+ therapeutic programs, including antibodies, small molecules, cell therapies, siRNA, and synthetic biology applications.

Read More →

NatmolAI™: Computational Expansion and Optimization of Natural-Product Chemical Space

Natural molecules remain a foundational source of bioactive compounds, yet their discovery and optimization are constrained by scarcity and structural complexity.

Read More →

Beauty Engineered: Ainnocence Launches CosmeticAI™ for AI-Driven Innovation in Skincare

CosmeticAI™ shifts early-stage discovery from experimental screening to in silico design, generating large populations of candidate molecules.

Read More →

AI Meets the Formula: Predictive Intelligence Redefines Chemical Design and Manufacturing

Using a formula-centered knowledge graph combined with process-level digital twin simulations, FormulaAI™ predicts formulation stability and compatibility.

Read More →

From Code to Cure: Accelerating Oligonucleotide Design with AI

Oligonucleotide engineering has traditionally been slowed by challenges in sequence selection, immunogenicity, durability, and delivery compatibility.

Read More →

Ainnocence Announces AI Platform for Material Performance Prediction

Material AI operates on the same computational backbone powering Ainnocence's platforms in small molecules, biologics and RNA therapeutics.

Read More →

Stay Updated

Subscribe to our newsletter for the latest news, research updates, and company announcements.